#1 Clinical Trials Search in Europe

Alogliptin

Clinical trials investigating Alogliptin are studying how it performs in people with type 2 diabetes. These trials focus on treatment effects in adult participants and measure outcomes such as change in HbA1c, a blood test that shows average blood sugar over time.

Table of contents

Trial overview

The source data include one clinical trial that lists Alogliptin in the treatment set for adults with type 2 diabetes.[1] The study is identified as NCT05433584 and is titled “A Study of Tirzepatide Compared with Intensified Conventional Care in Adult Participants with Type 2 Diabetes (SURPASS-EARLY).”[1]

The trial status is Authorised, and the study type is Interventional, which means researchers are assigning treatments and measuring the results.[1]

Who can participate

The target population in the trial is adult participants with type 2 diabetes.[1] The source does not provide more detailed entry rules, such as exact age limits, lab values, or other health conditions.[1]

  • Adults: people who are old enough to join an adult study group.[1]
  • Type 2 diabetes: the condition being studied in this trial.[1]

Study design and phase

The trial is in Phase 3, which is a later stage of clinical research.[1] Phase 3 studies usually look at how well a treatment works in a larger group of people and continue to collect important safety and effectiveness information.[1]

The enrollment is listed as 781, meaning 781 participants are included or planned for the study.[1]

What is being measured

The primary outcome is change from baseline in Hemoglobin A1c (HbA1c).[1] HbA1c is a blood test that shows average blood sugar over about 2 to 3 months.[1] “Baseline” means the starting measurement before treatment begins.[1]

The brief summary states that the study aims to show that tirzepatide is non-inferior to intensified conventional care for HbA1c change from baseline to Week 104.[1] Non-inferior means the new treatment is not worse than the comparison treatment by more than a set amount.[1]

Trial context and treatments listed

The intervention list in the source includes many diabetes medicines, including Alogliptin, along with other listed treatments such as sitagliptin, linagliptin, semaglutide, tirzepatide, dulaglutide, exenatide, liraglutide, lixisenatide, saxagliptin, vildagliptin, pioglitazone, metformin, and metformin with sulfonamides.[1]

Some entries in the intervention list are shown as “-” with a dose and route, which likely reflects comparator or placeholder treatment entries in the source record, but the source does not explain them further.[1]

For patients reading the trial record, the most important point is that Alogliptin appears in a study focused on diabetes treatment comparison and blood sugar control, not as a standalone drug monograph.[1]

Patient-friendly terms

Interventional study means researchers give a treatment and then watch what happens.[1] Primary outcome means the main result the study is built to measure.[1] Week 104 means the study looks at results after 104 weeks, or about 2 years.[1]

Intensified conventional care means standard treatment that is adjusted more closely or more strongly to improve diabetes control.[1] This helps researchers compare how the study treatment performs against usual care that has been stepped up.[1]

Trial ID Phase Condition studied Status Enrollment
NCT05433584 Phase 3 Type 2 Diabetes Authorised 781

FAQ

  • What are clinical trials of Alogliptin studying? The trial data provided show Alogliptin being studied in adults with type 2 diabetes. The main focus is on treatment effect, especially change in HbA1c over time.
  • Who can take part in these Alogliptin trials? The available trial includes adult participants with type 2 diabetes. The source does not give more detailed entry rules.
  • What phase are the Alogliptin trials? The trial listed in the source is a Phase 3 study. Phase 3 trials usually compare treatments in larger groups of people to see how well they work.
  • What outcome is being measured? The main outcome is change from baseline in hemoglobin A1c, also called HbA1c. Baseline means the starting point before treatment.
  • How many people are in the trial? The study lists an enrollment of 781 participants. Enrollment means the number of people planned or included in the trial.

Ongoing Clinical Trials on Alogliptin

  • Evaluation of Long-Term Efficacy and Safety of Tirzepatide Versus Intensified Conventional Care in Early Treatment of Type 2 Diabetes in Adults

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Czechia Germany Italy Romania Slovakia

Glossary

  • Type 2 diabetes: A long-term condition where the body does not use blood sugar well, which can lead to high blood sugar levels.
  • Adult participants: People who are 18 years or older and take part in a clinical trial.
  • Phase 3: A late stage of clinical research that studies how well a treatment works and continues to watch safety in a larger group.
  • Interventional study: A study where researchers assign a treatment or care plan and then measure the results.
  • HbA1c: A blood test that shows the average blood sugar level over the past 2 to 3 months.
  • Baseline: The starting point before treatment begins. Results are often compared with this starting value.
  • Change from baseline: The difference between the starting measurement and the later measurement after treatment.
  • Non-inferior: A result meaning one treatment is not worse than another by more than a set amount.
  • Intensified conventional care: Standard diabetes care that is made stronger or adjusted more closely to help improve results.
  • Enrollment: The number of people planned or included in a clinical trial.

References